Adria Juanola

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 56 publications

Long-Term Albumin Therapy in Cirrhosis With Ascites: Not an Answer yet.

Long-Term Albumin Therapy in Cirrhosis With Ascites: Not an Answer yet.

Journal: United European gastroenterology journal

Published: July 30, 2026

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.

Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis.

Journal: Journal of hepatology

Published: October 25, 2025

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Journal: Lancet (London, England)

Published: September 17, 2025

Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: Enough, but not too much.

Plasma volume expansion in patients with cirrhosis, ascites and acute kidney injury: Enough, but not too much.

Journal: Journal of hepatology

Published: July 25, 2025

PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study.

PD-L1 and the risk of bacterial infection in patients with chronic liver diseases: An international multicohort study.

Journal: JHEP reports : innovation in hepatology

Published: June 28, 2025

LiverRisk score (LRS) predicts long-term liver-related outcomes in a cohort of Veterans without evidence of liver disease.

LiverRisk score (LRS) predicts long-term liver-related outcomes in a cohort of Veterans without evidence of liver disease.

Journal: Hepatology (Baltimore, Md.)

Published: May 14, 2025

Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.

Real-World Use of Terlipressin in Cirrhosis and Acute Kidney Injury: Frequent Use Beyond Hepatorenal Syndrome.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: May 10, 2025

Urine Proteomics in Cirrhosis and Acute Kidney Injury: Insights Into the Pathogenesis of Hepatorenal Syndrome.

Urine Proteomics in Cirrhosis and Acute Kidney Injury: Insights Into the Pathogenesis of Hepatorenal Syndrome.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: April 16, 2025

Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter.

Marked Variation in Hepatic Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Over 5 Years: A Community-Based Study Using Controlled Attenuation Parameter.

Journal: United European gastroenterology journal

Published: March 21, 2025

Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus.

Albumin infusion in hepatorenal syndrome-acute kidney injury: New evidence challenges recent consensus.

Journal: Journal of hepatology

Published: March 19, 2025

Revisiting the use of albumin in patients with cirrhosis - trial design matters.

Revisiting the use of albumin in patients with cirrhosis - trial design matters.

Journal: Journal of hepatology

Published: February 06, 2025

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.

Simvastatin and Rifaximin in Decompensated Cirrhosis: A Randomized Clinical Trial.

Journal: JAMA

Published: February 05, 2025

Showing 1-12 of 56

Last Updated: 09/26/2026